angiosoma inc – publicly traded as otcqbsoan toggle navigation angiosoma inc publicly traded as otcqbsoan november   thomas clayy home  angiosoma inc publiclytraded clinical stage biotechnology company ticker soan audio interview with david p summers phd httpangiosomainfowpcontentuploadsupticknetworksoaninterviewmpreleased on october   uptick newswire’s jasyn blair interviewes david summers phdlatest event  november  shareholder presentation view in  pdf  ppt angiosoma inc ticker soan status fully reporting sec reporting current latest filing q business description angiosoma inc a nevada corporation is a clinical stage biotechnology company focused on improving the effectiveness of current standardofcare treatments especially related to endovascular interventions in the treatment of peripheral artery disease pad the company is developing its lead product a drug candidate called liprostintm for the treatment of peripheral artery disease or pad which has completed fda phase i and three phase ii clinical trials we are in discussions with several contract research organizations for completion of our fda protocol for phase iii and submission of our new drug application for marketing in the us and its territories authorized shares  ao oct   outstanding shares  ao oct   recent newsangiosoma inc starts soma nutraceuticals inc’s operationsapril  november  shareholder presentationnovember  angiosoma inc acquires patented nutraceutical for muscle mass developmentnovember  angiosoma inc to upgrade its omnicath patents into omnicath  atherectomy catheternovember  as a publicly traded company angiosoma inc provides news on its operations through press release distributors like business wire but it provides the same news here in an expanded format with links to all of the initial released locations and expanded images this conforms to regulation fd disclosure requirements products in pipelineliprostinliprostin™ angiosoma inc’s flagship product in its product pipeline is a peripheral artery disease ‘pad‘ therapy using fda approved alprostadil™ a prostaglandin referred to as pge packaged inside a proprietary… read more →transdermal pge patchin september  angiosoma inc with its chairman emeritus david p ‘doc‘ summers phd filed  provisional us patents and  nonprovisional us patents announced october   in a press release entitled ‘angiosoma inc files … read more →omnicathsoan is filing new patents currently which will in conjunction with the original base patent create the omnicath® ii angiosoma research inc a wholly owned texas subsidiary own patents associated with the omnicath® i read more →nutraceuticalsthese products have previously generated over ten million dollars  in sales through various sales outlets including gnc while these products were owned and marketed by endovasc inc in  and  read more →team angiosomaangiosoma inc’s team of professionals underscores the talent that has gone into our pipeline of products as well as the ability to bring those products to value for our shareholders alexanderia blankenship ceo ms blakenship has overseen the acquisition of intellectual property consisting of multiple patents from a private corporation david summers phd chairman emeritus ‘doc’ summers is our chairman emeritus and provides over  years of research and development of the products within our product pipeline a tomas garcia iii md scientific board of advisors dr garcia is a practicing physician in the field of cardiology for the past  years and the immediate past president of the texas medical association dr jackie r see md scientific board of advisors dr see is a cardiologist and the principal inventor and author of the patent corporate of microsphere technology “pgeedt” robert l sonfield corporate counsel with over  years of practice of law robert leon sonfield jr esq is one of the founders of angiosoma inc as well as its corporate counsel our core values for stockholdersaudio interviewinvestors will want to listen to the interview with dr summers httpsonlinehomeuswpcontentuploadsupticknetworksoaninterviewmpinvestors presentation  investors can download the november  investor presentation in pdf or as a power point pdf soanshareholderpresentationseptember filed patentsangiosoma inc files  new patent applications on liprostin™stock informationangiosoma inc ticker soan status fully reporting sec reporting current latest filing q authorized shares  ao oct   outstanding shares  ao oct   business description angiosoma inc a nevada corporation is a clinical stage biotechnology company focused on improving the effectiveness of current standardofcare treatments especially related to endovascular interventions in the treatment of peripheral artery disease pad the company is developing its lead product a drug candidate called liprostintm for the treatment of peripheral artery disease or pad which has completed fda phase i and three phase ii clinical trials we are in discussions with several contract research organizations for completion of our fda protocol for phase iii and submission of our new drug application for marketing in the us and its territories forward looking statementsangiosoma news releases and the information provided on this website contain forwardlooking information within the meaning of section a of the securities act of  and section e of the securities exchange act of  including statements that include the words “believes” “expects” “anticipate” or similar expressions such forwardlooking statements involve known and unknown risks and other factors that may cause the actual results performance or achievements of the company to differ materially from those expressed or implied by such forwardlooking statements in addition description of anyone’s past success is no guarantee of future success this news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereofassets our assets angiosoma inc has a robust product pipeline with patents provisional patents expired patents with corporate intellectual property  knowledge registered trademarks and many more to come here are the most important current corporate assets that contribute to our shareholder value liprostin™ pharmaceutical liprostin™ is a treatment for pad that has completed fda phase i and three phase ii clinical trials we are in discussions with contract research organizations “cro” for completion of our us food and drug administration “fda” protocol for phase iii and submission of our new drug application for marketing in the us and its territories transdermal pge patch the transdermal pge patch for the delivery of pge and  or liprostin™ through the skin for the treatment of cardiovascular diseases is part of a group of  provisional us patents and  nonprovisional us patents filed in september  by angiosoma inc omnicath i  omnicath ii the omnicath i is an atherectomy catheter that helps plaque removal by drilling pulverizing and shaving it the omnicath i is protected by us patent  and angiosoma inc is filing new patents currently which will in conjunction with the original base patent create the omnicath™ ii soma nutriceuticals inc soma nutriceuticals inc provides patented nutraceutical products that increase muscle mass as well as nonpatented nutraceutical products with proprietary formulas for aiding sleep erections stamina and other uses search for recent posts angiosoma inc starts soma nutraceuticals inc’s operations november  shareholder presentation angiosoma inc acquires patented nutraceutical for muscle mass development angiosoma inc to upgrade its omnicath patents into omnicath  atherectomy catheter uptick newswire talks with dr david summers follow me on twittermy tweetsmeta log in entries rss comments rss wordpressorg angiosoma inc files  new patent applications on liprostin™  business wire angiosoma inc files  new patent applications on liprostin™ october    am eastern daylight time montgomery texasbusiness wireangiosoma inc otcqb soan filed three  new patent applications associated with liprostin™ adding to the company’s product pipeline and supplementing the intellectual property already conveyed by chairman emeritus dr david p “doc” summers phd faca the new patents include transdermal skin patches and other methods of treating atherosclerosis commonly called peripheral artery disease ‘pad’ and coronary artery disease ‘cad’ “we are strengthening our flagship product liprostin™ which is a unique liposomal delivery of prostaglandin e ‘pge’ a naturally occurring hormone to treat the most pervasive and insidious disease in america pad  the atherosclerotic buildup of fatty plaque on blood vessel walls causing eventual blockage of blood flow pad is the same disease as cad that causes death by heart attack in coronary arteries” explained ms alexanderia k blankenship ceo  president of angiosoma inc “we are very fortunate to have a product that has successfully completed its us food and drug administration ‘fda’ phase i and ii trials and is ready to enter phase iii trials we are continuing to develop new ways to treat pad and cad such as with transdermal skin patches and subcutaneous pellets we have wide ranging intellectual property covering various treatment modalities including atherectomy catheters plaque scrappers and drug releasing stents” about angiosoma inc angiosoma inc httpwwwangiosomacom is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standardofcare treatments especially related to endovascular interventions in the treatment of peripheral artery disease pad our lead pharmaceutical product liprostin™ a treatment for pad has successfully completed fda phase i and three phase ii clinical trials and we are in discussions with several contract research organizations for rapid completion of our us food and drug administration fda approved protocol for phase iii with submission of our new drug application for marketing in the us and its territories notice regarding forward looking statements this news release contains forwardlooking information within the meaning of section a of the securities act of  and section e of the securities exchange act of  including statements that include the words “believes” “expects” “anticipate” or similar expressions such forwardlooking statements involve known and unknown risks and other factors that may cause the actual results performance or achievements of the company to differ materially from those expressed or implied by such forwardlooking statements in addition description of anyone’s past success is no guarantee of future success this news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof contacts angiosoma incalex blankenship  investorsangiosomacom release summary angiosoma inc files  new patent applications on liprostin™ adding to the companys product pipeline and supplementing the intellectual property already conveyed to the company contacts angiosoma incalex blankenship  investorsangiosomacom search advanced news search advanced news search log in sign up about us – angiosoma inc toggle navigation angiosoma inc publicly traded as otcqbsoan august   angiosoma about us angiosoma inc otcqbsoan is a clinical stage biotechnology company focused on improving the effectiveness of current standardofcare treatments related to pharmaceutical or endovascular interventions our “end to end” solution will provide interventional radiologists cardiologists and internal medicine physicians with both pharmaceutical and or endovascular interventional options prior to infarction or critical limb ischemic events stabilizing or reversing the atherosclerotic disease our soma nutraceutical inc subsidiary aims to provide dietary anti inflammatory blood thinning and anti clotting natural products as either stand alone or adjuncts to pharmaceutical care for pharmaceutical stabilization our liprostin™ product for treatment of peripheral artery disease “pad” completed preliminary us food and drug administration “fda” required phase i and phase ii clinical trials successfully and is entering phase iii prior to approval our angiosoma research inc subsidiary also owns the omnicath i  ii plaque debulking and vessel remodeling atherectomy catheter which will further support the stabilization of patients experiencing infarction or critical limb ischemic symptoms for long term preventative measures our transdermal pge patch will provide ongoing treatment for chronic cardiovascular disease by delivery of pge or liprostin™ through the skin in all we have a robust product pipeline from  years of research and development with existing patents provisional patents formulations and trademarks from previously successful products management scientific board of advisors investor information   our subsidiaries angiosoma research inc texas this was the subsidiary with all the intellectual property “ip” that was purchased in june  which was a precursor to first titan inc renaming itself to angiosoma inc soma nutraceuticals inc texas this is the subsidiary with all the ip purchased in november  for nutraceutical development marketing and development     by angiosoma inc all rights reserved share thisprintemaillinkedinfacebooktwittergoogle search for recent posts angiosoma inc starts soma nutraceuticals inc’s operations november  shareholder presentation angiosoma inc acquires patented nutraceutical for muscle mass development angiosoma inc to upgrade its omnicath patents into omnicath  atherectomy catheter uptick newswire talks with dr david summers follow me on twittermy tweetsmeta log in entries rss comments rss wordpressorg send to email address your name your email address cancel post was not sent  check your email addresses email check failed please try again sorry your blog cannot share posts by email angiosoma inc acquires patented nutraceutical for muscle mass developmenthomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hrs  minssp  dow  nasdaq angiosoma inc acquires patented nutraceutical for muscle mass developmentbusiness wirenovember  reblogsharetweetsharemontgomery texasbusiness wireangiosoma inc soan announces that its new subsidiary soma nutraceuticals inc is the recipient of intellectual property conveyed by its chairman emeritus dr david summers including a nutraceutical product using either natural or synthetic nicotine in a patented method for substantially accelerating the development of muscle mass and strength us patent  “development of muscle mass in a mammal” the product produced over  million in sales through gnc in  and  when the patent was owned by endovasc inc dr summers also conveyed additional intellectual properties including products for sleep staying awake  alert strength  stamina and a product for enhancing male libido while also aiding erectionsceo alexanderia blankenship said “we are excited about the potential of these new products and their ability to quickly produce substantial cash flow the muscle development product initially sold through gnc where it was once in the top ten selling products while the former patent licensee had a dispute which caused its discontinuance dr summers and angiosoma inc had nothing to do with the dispute and therefore we hope to quickly get the product selling through its previous sales channels including gnc”about angiosoma incangiosoma inc httpwwwangiosomacom is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standardofcare treatments especially related to endovascular interventions in the treatment of peripheral artery disease pad our lead pharmaceutical product liprostin™ a treatment for pad has successfully completed fda phase i and three phase ii clinical trials and we are in discussions with several contract research organizations for rapid completion of our us food and drug administration fda approved protocol for phase iii with submission of our new drug application for marketing in the us and its territoriesnotice regarding forward looking statementsthis news release contains forwardlooking information within the meaning of section a of the securities act of  and section e of the securities exchange act of  including statements that include the words “believes” “expects” “anticipate” or similar expressions such forwardlooking statements involve known and unknown risks and other factors that may cause the actual results performance or achievements of the company to differ materially from those expressed or implied by such forwardlooking statements in addition description of anyone’s past success is no guarantee of future success this news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereofview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextdonald trump thinks jeff bezos is his biggest threatyahoo financeengineer finds pattern makes millions in stocksmoney morningsponsoredheres trumps approval rating in every statebusiness insiderchinas army looks like its getting ready for something big to go down in north koreabusiness insidereconomists answer are we at full employmentyahoo finance videoa pennycrypto miracle making some americans richagora financialsponsoredfacebook earnings fed announcement — what you need to know in markets on wednesdayyahoo financeconservative media outlets are sending trump a big warning on jeff sessions — and trump is paying attentionbusiness insidersenate opens obamacare debate at last but outcome in doubtassociated pressstart earning miles with the best travel cardwise breadsponsoredfirst ‘avengers infinity war’ trailer leakedinvestorplaceformer obama official weighs in on trumps plan to bring back manufacturing jobsyahoo finance videowhy everybody should be happy that flash is finally dyingyahoo financewomen everywhere should carry this tiny devicesiren songsponsoreda conspiracy theory about chipotle is gaining steambusiness insiderus navy releases video showing close call and machinegun firing near an iranian patrol boatbusiness insiderboy scouts defend inviting trump amid backlash over president’s rambling speechliberaltroll trump goes to the boy scouts and makes everything about him nice huhjoin the conversation  k angiosoma inc acquires patented nutraceutical for muscle mass development  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street angiosoma inc acquires patented nutraceutical for muscle mass development business wire nov    am est angiosoma inc otcqb soan announces that its new subsidiary soma nutraceuticals inc is the recipient of intellectual property conveyed by its chairman emeritus dr david summers including a nutraceutical product using either natural or synthetic nicotine in a patented method for substantially accelerating the development of muscle mass and strength us patent   development of muscle mass in a mammal the product produced over  million in sales through gnc in  and  when the patent was owned by endovasc inc dr summers also conveyed additional intellectual properties including products for sleep staying awake  alert strength  stamina and a product for enhancing male libido while also aiding erections ceo alexanderia blankenship said  we are excited about the potential of these new products and their ability to quickly produce substantial cash flow the muscle development product initially sold through gnc where it was once in the top ten selling products while the former patent licensee had a dispute which caused its discontinuance dr summers and angiosoma inc had nothing to do with the dispute and therefore we hope to quickly get the product selling through its previous sales channels including gnc about angiosoma inc angiosoma inc  httpwwwangiosomacom is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standardofcare treatments especially related to endovascular interventions in the treatment of peripheral artery disease  pad our lead pharmaceutical product liprostin™ a treatment for pad has successfully completed fda phase i and three phase ii clinical trials and we are in discussions with several contract research organizations for rapid completion of our us food and drug administration  fda approved protocol for phase iii with submission of our new drug application for marketing in the us and its territories notice regarding forward looking statements this news release contains forwardlooking information within the meaning of section a of the securities act of  and section e of the securities exchange act of  including statements that include the words  believes  expects  anticipate or similar expressions such forwardlooking statements involve known and unknown risks and other factors that may cause the actual results performance or achievements of the company to differ materially from those expressed or implied by such forwardlooking statements in addition description of anyones past success is no guarantee of future success this news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof trending we found  products on amazon with inflated discount rates amds strong guidance points to share gains and more could be on the way ftc seen as set to block rite aid deal advanced micro devices could explode another  within hours chart honda accord through the years  reasons the  model is a really big deal advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers soanotc us stock quote  angiosoma inc  bloomberg markets error could not add to watchlist x  watchlist angiosoma inc soanus otc us usd   as of  pm edt  volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later there are currently no press releases for this ticker please check back later profile angiosoma inc is a clinical stage biotechnology company the company is focused on improving the effectiveness of current standardofcare treatments especially related to endovascular interventions in the treatment of peripheral artery disease pad address  walden roadsuite montgomery tx united states phone  website wwwangiosomacom executives board members alex k blankenship presceotreasurersecretary show more ppmh point to point methodics otc ppmh innovation technology point to point methodics inc otc ppmh point to point methodics inc is a publicly traded company listed on the otc our drive to create useful products that better our society and our minds our leadership we are lead by industry leading professionals dedicate to growth and value our objective to become an industry leader in our prospective product markets about us point to point methodics inc a publicly traded company otc ppmh focused on innovation and enterprise by acquiring managing and operating technology based companies for growth within the industry rugged outdoor computing systems inc tbx group inc greatday inc mpathdiscovery llc smacked ventures inc smacktive llc read more × the company is an ever evolving entity determined to be an industry leader in each market its products are showcased the company and its products are presently involved in the below stated markets automotivebusiness intelligencedigital sociologyeducational applicationsgaming applicationshomeland securityinformational understandingmobile applicationsmobile mappingpublic safetysocial media the company and its products have a global outreach for its customer base with the companys products being sold to or provided as a service to a customer base that stretches all the way from a elementary school child to fortune  companies our team leaders ceo president paul baioni cfo executive vp john miller rugged outdoor computing john whittaker smacktive smacked ventures sam feuer smacktive smacked ventures marcelo moyano mpath discovery richard neal × paul baioni chairman president  chief executive officer provides the company with a solid base of management experience in manufacturing service advertising and distribution industries he holds a masters degree in accounting a cpa certificate and has held operational financial and information technology positions in both large and small organizations including two previous startups mr baioni with amr services led the accounting and mis functions for a distribution startup that reached over m in annual sales in less than  years at which time the business was sold and went public his proven leadership skills and wide breadth of knowledge and understanding of business processes will guide a very skilled management team to achieving the anticipated future rapid growth and success of the company × john miller executive vice president  chief financial officer has extensive senior management experience helping corporations realize business opportunities successfully confront market challenges and create shareholder and corporate value he has provided executive leadership to help position companies at the forefront of their industry by ensuring production efficiency quality service and costeffective management of resources in addition to holding senior executive positions in several industries mr miller was also former senior vice president of federal express he started at fedex during their startup phase and spent over  years there including holding the position of chief financial officer mr miller was instrumental in various funding initiatives for federal express and was part of the management team that took the company public and listed it on the new york stock exchange his experience also includes assignments with other exceptional international and domestic companies private and public in diverse industries earlier in his career mr miller was one of the youngest division controllers in the history of ford motor company × john whittaker rugged outdoor computing systems directs the development prototyping testing and introduction to manufacturing of portable computing multi mode wireless and image processing systems for the rocs division of ppmh his unique approach involves traveling globally to work handson in the application laboratories of leading semiconductor corporations and component manufacturers and mr whittaker then brings these latest technologies architectures and techniques to rocs to apply to a line of cutting edge products that push ahead of the industry in feature sets and performancemr whittaker has over  years’ experience in computer design and manufacturing including high profile development for several fortune  companies and patented computer architecture mr whittaker holds bachelor of science degrees in both electrical engineering and mechanical engineering from christian brothers university × sam feuer smacktive  smacked ventures is a true successful entrepreneur founder of smacktive and several other successful companies including mindsmack which was rank  on the inc   as a brooklynraised individual mr feuer has successfully accomplished many executive and entrepreneurial goals and continues to personally field hundreds of daily emails and phone calls in addition to his deep commitment to his personal interacts with his team mr feuer continues to extend his tenacious hold on the media industry all the while defeating countless competitors in scrabble and learning to golf while rooting resoundingly for his beloved yankees × marcelo moyano smacktive  smacked ventures is a true pioneer of mobile internet and interactive experiences he is recognized around the world in the technology industry for his award winning work mr moyano possesses masterful skills in visual design animation sequences application development and has led fullscale projects for clients such as dreamworks citibank doritos mtv aol and countless others he is a technology ninja at the highest levelmr moyanos belief is that technology will help to change the way humans interact with each other and with everything around us this concept idea to build something to help people get together based on their likes and being able to spread that idea over the world is what makes me feel truly happy context is very important he is passionate about making things happen and if we can do that by using technology and reach millions of people at once then that’s something that i’m definitely going to be part of × richard neal mpathdiscovery mr richard neal has been credited with being the creator of the field of study known as digital sociology mr neal founder of mpathdiscovery received a bachelors in psychology from the university of georgia an emba from tulane university and a msci in technology from the university of maryland he has also been conferred honors in entrepreneurship and innovation from the kauffman foundation the state of missouri and the kansas city area development council in  he was selected for the cover of kc business magazine as an innovator mr neal was accepted into intellectual ventures led by the excto of microsoft nathan myhrvold as an invention development fund network member as well as darpa within their principle investigator ranks mr neals portfolio includes digitallybased memetic epidemiology gauging online auction markets a biofluid splash attenuator wildlife pathogenic load monitoring several industrial safety tools combinatorial nutritional supplements veterinary topical analgesics proprioceptionenhanced utensils for early childhood development an array of extreme weather endurance gear the design and construction of a customized electromagnet for paraferrous material removal from an aggregate flow useful in heavy industrial applications focused upon recycling as well as multiple expert systems and decision engines many of which are currently being used in the financial markets business and market intelligence realm  public company  subsidiaries  products endless potential sampling of our products     full view full view full view full view full view full view full view investor relations point to point methodics inc is a public company listed on the otc under the symbol ppmh for stock price updates filling information details and company profile please click here click here to view recent company news web presence digital sociology learn about the field of study known as digital sociology mpathdiscovery actionable intelligence™ is the use of digital sociology applied to business intelligence smacked ventures mobile gaming and all things fun smacktive social media app to meet up and get active fastmall interactive shopping navigation featuring mapos™ greatday a development company focused on the automotive industry mapos™ mapos™ is the worlds first and only patent pending non gps or wifi turnbyturn navigation technology nashpeeps country music videos and more tbx group managing the operations of innovation and technology rocs rugged outdoor computing systems dedicated to public safety and law enforcement technologies chosenapps™ app directory for both apple and android devices contact us point to point methodics inc  s shady grove rd suite memphis tn usa telephone      email  infoppmhinccom   point to point methodics inc all rights reserved the app that helps you find people nearby to share activities together find people in your area message chat and meet angiosoma inc announces a liprostin™ focused joint venture  business wire angiosoma inc announces a liprostin™ focused joint venture october    am eastern daylight time montgomery texasbusiness wireangiosoma inc otcqbsoan announces a joint venture with la jolla capital partners llc ‘la jolla’ focused on the funding and management of us food and drug administration ‘fda’ liprostin™ phase iii trials as well as the licensing of liprostin™ worldwide thereafter liprostin™ is a liposomal encapsulated prostaglandin e ‘pge’ and is angiosoma inc’s flagship product la jolla personnel have extensive experience in the fda regulatory environment both in funding and management of the process and have a successful product licensing history “if liprostin™ treated ten percent  of the  million untreated peripheral artery disease patients in the us as reported by the american heart association this could produce a gross income of six hundred million dollars  million if we assumed the company yields five hundred dollars  per patient” said ms alexanderia k blankenship ceo  president of angiosoma inc mr c richard piazza president of la jolla capital partners llc has experience that directly relates to the future success of liprostin™ phase iii fda trials and in conjunction with bruce badeau at la jolla have a history of funding the process associated with those trials successfully mr piazza said “angiosoma inc’s liprostin™ is in a rather unique position as it has completed phase i and phase ii clinical trials this puts angiosoma inc in a position that most small companies never reach – at the brink of phase iii fda trials with a possibly huge licensing opportunity” angiosoma inc made its september  shareholder presentation available at its website httpangiosomacomshareholderpresentationseptember about angiosoma inc angiosoma inc httpwwwangiosomacom is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standardofcare treatments especially related to endovascular interventions in the treatment of peripheral artery disease pad our lead pharmaceutical product liprostin™ a treatment for pad has successfully completed fda phase i and three phase ii clinical trials and we are in discussions with several contract research organizations for rapid completion of our us food and drug administration fda approved protocol for phase iii with submission of our new drug application for marketing in the us and its territories notice regarding forward looking statements this news release contains forwardlooking information within the meaning of section a of the securities act of  and section e of the securities exchange act of  including statements that include the words “believes” “expects” “anticipate” or similar expressions such forwardlooking statements involve known and unknown risks and other factors that may cause the actual results performance or achievements of the company to differ materially from those expressed or implied by such forwardlooking statements in addition description of anyone’s past success is no guarantee of future success this news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof contacts angiosoma incalex blankenship investorsangiosomacom release summary angiosoma inc announces a liprostin™ focused joint venture with la jolla capital partners llc contacts angiosoma incalex blankenship investorsangiosomacom search advanced news search advanced news search log in sign up angiosoma inc acquires patented nutraceutical for muscle mass development  otcmarketscom otc markets   home marketplaces market activity current market closing summary broker dealer data corporate actions short sale data reg sho data news company news  financials press releases videos  presentations rss feeds otc markets events otc markets newsletter otc markets press center services companies investors market data otc link® ats research stock screener otcqx company list company directory service provider directory otcqx sponsors research marketplace broker dealer directory prohibited attorney list symbology glossary learn our marketplaces market  investor protection reporting requirements american depositary receipts adrs how to get traded caveat emptor policy finra  sec rules whitepapers faqs         company directory  stock screener otc market totals  securities  dollar volume  share volume  trades   quote charts company profile news financials filings and disclosure short sales insider disclosure research reports videos and presentations soan angiosoma inc   common stock sec reporting  current pink current information   otc disclosure  news service   angiosoma inc acquires patented nutraceutical for muscle mass development nov   otc disclosure  news service  angiosoma inc otcqb soan announces that its new subsidiary soma nutraceuticals inc is the recipient of intellectual property conveyed by its chairman emeritus dr david summers including a nutraceutical product using either natural or synthetic nicotine in a patented method for substantially accelerating the development of muscle mass and strength us patent  “development of muscle mass in a mammal” the product produced over  million in sales through gnc in  and  when the patent was owned by endovasc inc dr summers also conveyed additional intellectual properties including products for sleep staying awake  alert strength  stamina and a product for enhancing male libido while also aiding erections ceo alexanderia blankenship said “we are excited about the potential of these new products and their ability to quickly produce substantial cash flow the muscle development product initially sold through gnc where it was once in the top ten selling products while the former patent licensee had a dispute which caused its discontinuance dr summers and angiosoma inc had nothing to do with the dispute and therefore we hope to quickly get the product selling through its previous sales channels including gnc” about angiosoma inc angiosoma inc httpwwwangiosomacom is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standardofcare treatments especially related to endovascular interventions in the treatment of peripheral artery disease pad our lead pharmaceutical product liprostin™ a treatment for pad has successfully completed fda phase i and three phase ii clinical trials and we are in discussions with several contract research organizations for rapid completion of our us food and drug administration fda approved protocol for phase iii with submission of our new drug application for marketing in the us and its territories notice regarding forward looking statements this news release contains forwardlooking information within the meaning of section a of the securities act of  and section e of the securities exchange act of  including statements that include the words “believes” “expects” “anticipate” or similar expressions such forwardlooking statements involve known and unknown risks and other factors that may cause the actual results performance or achievements of the company to differ materially from those expressed or implied by such forwardlooking statements in addition description of anyone’s past success is no guarantee of future success this news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof view source version on businesswirecom httpwwwbusinesswirecomnewshomeen copyright   businesswire all rights reserved the above news release has been provided by the above company via the otc disclosure and news service issuers of news releases and not otc markets group inc are solely responsible for the accuracy of such news releases   angiosoma inc announces a liprostin™ focused joint venture  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street angiosoma inc announces a liprostin™ focused joint venture business wire oct    am edt angiosoma inc otcqbsoan announces a joint venture with la jolla capital partners llc  la jolla focused on the funding and management of us food and drug administration  fda liprostin™ phase iii trials as well as the licensing of liprostin™ worldwide thereafter liprostin™ is a liposomal encapsulated prostaglandin e pge and is angiosoma incs flagship product la jolla personnel have extensive experience in the fda regulatory environment both in funding and management of the process and have a successful product licensing history  if liprostin™ treated ten percent  of the  million untreated peripheral artery disease patients in the us as reported by the american heart association this could produce a gross income of six hundred million dollars  million if we assumed the company yields five hundred dollars  per patient said ms alexanderia k blankenship ceo  president of angiosoma inc mr c richard piazza president of la jolla capital partners llc has experience that directly relates to the future success of liprostin™ phase iii fda trials and in conjunction with bruce badeau at la jolla have a history of funding the process associated with those trials successfully mr piazza said  angiosoma incs liprostin™ is in a rather unique position as it has completed phase i and phase ii clinical trials this puts angiosoma inc in a position that most small companies never reach  at the brink of phase iii fda trials with a possibly huge licensing opportunity angiosoma inc made its september  shareholder presentation available at its website  httpangiosomacomshareholderpresentationseptember about angiosoma inc angiosoma inc  httpwwwangiosomacom is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standardofcare treatments especially related to endovascular interventions in the treatment of peripheral artery disease  pad our lead pharmaceutical product liprostin™ a treatment for pad has successfully completed fda phase i and three phase ii clinical trials and we are in discussions with several contract research organizations for rapid completion of our us food and drug administration  fda approved protocol for phase iii with submission of our new drug application for marketing in the us and its territories notice regarding forward looking statements this news release contains forwardlooking information within the meaning of section a of the securities act of  and section e of the securities exchange act of  including statements that include the words  believes  expects  anticipate or similar expressions such forwardlooking statements involve known and unknown risks and other factors that may cause the actual results performance or achievements of the company to differ materially from those expressed or implied by such forwardlooking statements in addition description of anyones past success is no guarantee of future success this news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof trending we found  products on amazon with inflated discount rates amds strong guidance points to share gains and more could be on the way ftc seen as set to block rite aid deal advanced micro devices could explode another  within hours chart honda accord through the years  reasons the  model is a really big deal advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers